Medical Biotechnology MCQs (Set-3)

Difficulty: Medium

To compare RNA expression between treated and untreated cells, which workflow is appropriate?

A measure total antibody by ELISA
B isolate RNA, reverse-transcribe it to cDNA, then quantify with real-time PCR
C amplify the RNA directly with DNA polymerase alone
D sequence a protein after Western blot

Which qPCR control helps detect contamination introduced during reaction setup?

A a no-template control
B an uninfected cell culture with no PCR reagents
C a protein ladder
D a positive sample only

Suppose two samples are tested with the same validated qPCR assay and one crosses threshold several cycles earlier. The earlier sample likely had

A more antibody but no nucleic acid
B less starting target nucleic acid
C more starting target nucleic acid
D no target at all

A diagnostic lab must detect an antigen when the sample may contain many unrelated proteins. Why use a capture antibody plus a second antibody?

A two antibodies amplify DNA directly
B two specific binding steps improve target recognition in a sandwich assay
C the antibodies convert antigen into RNA
D the second antibody prevents all nonspecific binding by itself

A genetic test detects a variant in a tumor sample but not in blood cells. Which interpretation is plausible?

A the variant may be somatic and limited to tumor cells
B the blood test proves the tumor result false
C the sample contains no DNA
D the variant must be inherited by every cell

A laboratory measures a biomarker in a small cohort and obtains a promising result. What is the best next step before clinical use?

A announce a diagnosis from the pilot alone
B assume the result applies to every population
C validate the assay and result in independent, appropriately designed cohorts
D remove the negative controls

A new PCR assay amplifies a related but nontarget gene. Which assay property is inadequate?

A sample volume
B sensitivity
C cell viability
D analytical specificity

A patient sample tests negative for target DNA, but the internal amplification control also fails. How should the result be handled?

A as a positive antibody result
B as proof of immunity
C as invalid or inconclusive, then investigate inhibition or processing failure
D as a definitive negative

A DNA microarray includes probes for known variants. Which limitation follows from this design?

A it edits the tested DNA
B it always detects every possible mutation
C it directly measures protein activity
D it may miss variants not represented by probes

An NGS test reports a variant of uncertain significance. Which action best supports responsible interpretation?

A review evidence and avoid treating uncertainty as a confirmed diagnosis
B label it pathogenic without follow-up
C ignore quality metrics
D assume every rare variant causes disease

A patient-specific therapy uses the patient’s own cells. Which term describes the cell source?

A xenogeneic
B syngeneic plant
C autologous
D allogeneic

A donor-derived cell product is given to a different patient. It is

A autologous
B pluripotent by definition
C allogeneic
D monoclonal

A CAR-T product is genetically modified ex vivo. Which release tests are especially relevant?

A leaf shape and chlorophyll
B identity, viability, potency, sterility, and genetic modification
C only the patient’s blood type
D the donor’s eye color

A gene-therapy vector is designed to deliver a normal copy of a gene to somatic cells. Which outcome is intended?

A restore or supplement the function of the affected cells
B make the target cells produce antibodies against every protein
C remove all immune memory
D edit every germ cell in the patient

An immune response against a viral vector reduces transduced-cell persistence. Which design concern should be considered?

A whether the patient has plant allergies
B the number of PCR primers in a separate diagnostic assay
C the fluorescence of a DNA ladder
D pre-existing or induced immunity to the vector

In a cell-therapy potency assay, what is being measured?

A the color of the shipping container
B the number of labels on the vial
C the patient’s genome sequence only
D whether the product performs its intended biological function

An ELISA’s negative control gives a strong signal. Which problem is most likely?

A nonspecific binding, contamination, or inadequate washing
B the antigen is definitely absent
C the standard curve is unnecessary
D the test has perfect sensitivity

A pharmacogenomic test finds a variant that changes enzyme activity. What information can it support?

A a definitive diagnosis of every disease
B proof that a drug will work in every patient
C a prediction about drug metabolism that may inform treatment choices
D the exact concentration of a drug without measuring it

A qPCR standard curve is used to estimate target quantity. What relationship is calibrated?

A protein band location versus pH only
B cycle threshold versus known template concentrations
C antibody color versus cell size
D vessel volume versus DNA sequence

A diagnostic study has many healthy participants but few affected cases. Which performance measure may be estimated imprecisely?

A PCR cycle temperature
B sensitivity
C reagent volume
D sample storage time

A test is used to screen a low-prevalence population. Why can many positive results still be false positives even with good specificity?

A positive predictive value depends on prevalence as well as test performance
B the test begins amplifying unrelated proteins
C prevalence never affects interpretation
D sensitivity becomes zero

A recombinant protein has the correct amino-acid sequence but poor activity. Which factor should be examined?

A whether the gene has a stop codon in the DNA ladder
B the color of the bacterial colony only
C folding, processing, and post-translational modifications
D the number of microscope slides

A therapeutic monoclonal antibody is glycosylated differently from the reference product. Why can this matter?

A it guarantees identical potency
B it removes the need for clinical evaluation
C it changes the antibody into DNA
D glycosylation can affect biological activity or other product properties

A gene therapy product is intended for one organ, but vector DNA is detected elsewhere. What should be assessed?

A only the intended organ’s color
B biodistribution and off-target exposure
C the patient’s blood group alone
D the PCR thermocycler brand

An edited cell product contains unintended genomic changes. Which quality concern is raised?

A cryopreservation temperature of a different product
B ELISA signal amplification
C antibody specificity only
D genomic integrity and off-target effects